Pub Date : 2025-10-01DOI: 10.1038/s41584-025-01302-0
Derin Karacabeyli, Diane Lacaille
Obesity affects nearly one in six adults worldwide. Excess adiposity is a pro-inflammatory state associated with increased risk of several types of arthritis, increased arthritis disease activity and/or severity, and poorer response to certain treatments. Obesity is a major risk factor for cardiovascular disease, the leading cause of death in people with common arthritides such as osteoarthritis (OA), gout, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising therapeutic option for people with arthritis and obesity or type 2 diabetes mellitus owing to their pleiotropic effects, including weight loss, improved survival and reduced risk of major cardiovascular and renal events. In vitro and preclinical in vivo experiments in arthritis have uncovered weight-loss-independent anti-inflammatory and chondroprotective properties of GLP-1RAs. In knee OA, clinical data suggest that GLP-1RAs improve pain and function and reduce the risk of surgical intervention; however, their effects on OA incidence remain incompletely understood. Evidence suggests that GLP-1RAs do not directly prevent gout attacks, but are effective in managing cardiometabolic conditions commonly associated with gout and other arthritides. More research is needed to clarify the effects of GLP-1RAs on incidence, disease activity, and progression of rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss. In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.
{"title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","authors":"Derin Karacabeyli, Diane Lacaille","doi":"10.1038/s41584-025-01302-0","DOIUrl":"10.1038/s41584-025-01302-0","url":null,"abstract":"Obesity affects nearly one in six adults worldwide. Excess adiposity is a pro-inflammatory state associated with increased risk of several types of arthritis, increased arthritis disease activity and/or severity, and poorer response to certain treatments. Obesity is a major risk factor for cardiovascular disease, the leading cause of death in people with common arthritides such as osteoarthritis (OA), gout, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising therapeutic option for people with arthritis and obesity or type 2 diabetes mellitus owing to their pleiotropic effects, including weight loss, improved survival and reduced risk of major cardiovascular and renal events. In vitro and preclinical in vivo experiments in arthritis have uncovered weight-loss-independent anti-inflammatory and chondroprotective properties of GLP-1RAs. In knee OA, clinical data suggest that GLP-1RAs improve pain and function and reduce the risk of surgical intervention; however, their effects on OA incidence remain incompletely understood. Evidence suggests that GLP-1RAs do not directly prevent gout attacks, but are effective in managing cardiometabolic conditions commonly associated with gout and other arthritides. More research is needed to clarify the effects of GLP-1RAs on incidence, disease activity, and progression of rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss. In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"671-683"},"PeriodicalIF":32.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41584-025-01313-x
Maria Papatriantafyllou
Infused lipid nanoparticles were successfully used to generate CAR-T cells in patients with refractory systemic lupus erythematosus, achieving B cell depletion.
输注脂质纳米颗粒成功用于难治性系统性红斑狼疮患者产生CAR-T细胞，实现B细胞耗竭。
{"title":"In vivo CAR-T cell engineering in refractory SLE","authors":"Maria Papatriantafyllou","doi":"10.1038/s41584-025-01313-x","DOIUrl":"10.1038/s41584-025-01313-x","url":null,"abstract":"Infused lipid nanoparticles were successfully used to generate CAR-T cells in patients with refractory systemic lupus erythematosus, achieving B cell depletion.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 12","pages":"697-697"},"PeriodicalIF":32.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41584-025-01312-y
Holly Webster
Although DADA2 is typically described as an autosomal recessive disease, it can also present in individuals who are heterozygous for specific ADA2 variants.
虽然DADA2通常被描述为常染色体隐性遗传病，但它也可以出现在特定ADA2变异的杂合个体中。
{"title":"DADA2 as an autosomal dominant disease","authors":"Holly Webster","doi":"10.1038/s41584-025-01312-y","DOIUrl":"10.1038/s41584-025-01312-y","url":null,"abstract":"Although DADA2 is typically described as an autosomal recessive disease, it can also present in individuals who are heterozygous for specific ADA2 variants.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"650-650"},"PeriodicalIF":32.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this Viewpoint article, six patients and patient advocates discuss the role of the patient in rheumatology, the current unmet needs of patients and promising advances. By reflecting on their own lived experiences, the authors emphasize the integral role of patients for progress in the field.
{"title":"The role of the patient in rheumatology","authors":"Jeanette Andersen, Janet Church, Seth Durrant, Sue Farrington, Noriko Okochi, Natasha Trehan","doi":"10.1038/s41584-025-01303-z","DOIUrl":"10.1038/s41584-025-01303-z","url":null,"abstract":"In this Viewpoint article, six patients and patient advocates discuss the role of the patient in rheumatology, the current unmet needs of patients and promising advances. By reflecting on their own lived experiences, the authors emphasize the integral role of patients for progress in the field.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"651-656"},"PeriodicalIF":32.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-30DOI: 10.1038/s41584-025-01314-w
Nicholas Fuggle, René Rizzoli, Charlotte Beaudart, Bernard Cortet, Elizabeth M. Curtis, Mickaël Hiligsmann, Jean-Marc Kaufman, Nicola Veronese, Ben Hur Albergaria, Nasser Al-Daghri, Majed Alokail, Maria Luisa Brandi, Olivier Bruyère, Nansa Burlet, Claudia Campusano, Enrique Casado, Etienne Cavalier, Manju Chandran, Cyrus Cooper, Patrizia D’Amelio, Bess Dawson-Hughes, Peter R. Ebeling, John A. Kanis, Andreas Kurth, Radmila Matijevic, Eugene McCloskey, Michael McClung, Ouafa Mkinsi, Ngozi Njeze, Régis P. Radermecker, François Rannou, Stuart Silverman, Şansın Tüzün, Leith Zakraoui, Jean-Yves Reginster, Nicholas C. Harvey
{"title":"Author Correction: Parathyroid hormone receptor agonists in the management of osteoporosis","authors":"Nicholas Fuggle, René Rizzoli, Charlotte Beaudart, Bernard Cortet, Elizabeth M. Curtis, Mickaël Hiligsmann, Jean-Marc Kaufman, Nicola Veronese, Ben Hur Albergaria, Nasser Al-Daghri, Majed Alokail, Maria Luisa Brandi, Olivier Bruyère, Nansa Burlet, Claudia Campusano, Enrique Casado, Etienne Cavalier, Manju Chandran, Cyrus Cooper, Patrizia D’Amelio, Bess Dawson-Hughes, Peter R. Ebeling, John A. Kanis, Andreas Kurth, Radmila Matijevic, Eugene McCloskey, Michael McClung, Ouafa Mkinsi, Ngozi Njeze, Régis P. Radermecker, François Rannou, Stuart Silverman, Şansın Tüzün, Leith Zakraoui, Jean-Yves Reginster, Nicholas C. Harvey","doi":"10.1038/s41584-025-01314-w","DOIUrl":"10.1038/s41584-025-01314-w","url":null,"abstract":"","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 12","pages":"756-756"},"PeriodicalIF":32.7,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41584-025-01314-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29DOI: 10.1038/s41584-025-01308-8
Peter E. Lipsky
Both rheumatology and the publishing environment have seen tremendous changes over the past two decades. Here, the first Editor in-Chief reflects on the challenges faced by this journal and what it has taken to remain at the forefront of the field.
{"title":"20 years of Nature Reviews Rheumatology","authors":"Peter E. Lipsky","doi":"10.1038/s41584-025-01308-8","DOIUrl":"10.1038/s41584-025-01308-8","url":null,"abstract":"Both rheumatology and the publishing environment have seen tremendous changes over the past two decades. Here, the first Editor in-Chief reflects on the challenges faced by this journal and what it has taken to remain at the forefront of the field.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"642-643"},"PeriodicalIF":32.7,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-25DOI: 10.1038/s41584-025-01304-y
Francis Berenbaum, Emmanuel Maheu
In the past two decades the field of hand osteoarthritis (OA) has moved from resignation to action. Despite progress, such as the recognition of the phenotypic heterogeneity of hand OA (including inflammation- and/or metabolic syndrome-associated hand OA) and the standardization of imaging and treatment outcomes, challenges remain in achieving truly disease-modifying therapies.
{"title":"A firm grip on hand OA: 20 years of progress and prospects","authors":"Francis Berenbaum, Emmanuel Maheu","doi":"10.1038/s41584-025-01304-y","DOIUrl":"10.1038/s41584-025-01304-y","url":null,"abstract":"In the past two decades the field of hand osteoarthritis (OA) has moved from resignation to action. Despite progress, such as the recognition of the phenotypic heterogeneity of hand OA (including inflammation- and/or metabolic syndrome-associated hand OA) and the standardization of imaging and treatment outcomes, challenges remain in achieving truly disease-modifying therapies.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"646-647"},"PeriodicalIF":32.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-23DOI: 10.1038/s41584-025-01307-9
Ashira D. Blazer, Grace C. Wright
The collective priorities of the rheumatology field represent the lived experience, and therefore diversity of its members. The ‘mould’ of rheumatology, that is, its culture, structures and expectations, was not created for or by women, but women have slowly changed this mould to make space for diverse perspectives.
{"title":"A 20-year reflection on women in rheumatology","authors":"Ashira D. Blazer, Grace C. Wright","doi":"10.1038/s41584-025-01307-9","DOIUrl":"10.1038/s41584-025-01307-9","url":null,"abstract":"The collective priorities of the rheumatology field represent the lived experience, and therefore diversity of its members. The ‘mould’ of rheumatology, that is, its culture, structures and expectations, was not created for or by women, but women have slowly changed this mould to make space for diverse perspectives.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 11","pages":"648-649"},"PeriodicalIF":32.7,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-15DOI: 10.1038/s41584-025-01286-x
John D. Reveille, Lihi Eder, Nelly Ziade, Percival D. Sampaio-Barros, Tae-Hwan Kim, Nurullah Akkoç, Matthew A. Brown
The worldwide epidemiology of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and peripheral spondyloarthritis, as well as of HLA-B27 and other MHC and non-MHC genes in these diseases, is reviewed herein. The frequency of axSpA is highest in circumpolar groups (such as Sami people and certain Indigenous American groups) and lowest in those of Japanese and African ancestry. The same pattern holds for PsA, although the overall prevalence of PsA seems much lower in East Asia, where it is less frequent than axSpA. The prevalence of PsA in people with psoriasis is increased where rheumatological assessment was carried out and seems to be increasing over time. HLA-B27 remains the most important genetic factor in axSpA susceptibility, although its frequency is lower in African American, South American and Middle Eastern populations than in others. The presence of HLA-B27 and other HLA alleles seems to be important in discerning clinical subsets of SpA and PsA, particularly those characterized by acute anterior uveitis or by axSpA with psoriasis, although these HLA-B27 and other MHC and non-MHC associations are derived from genome-wide association studies and other chip-based studies in large populations. These studies have been carried out mainly in populations of European and East Asian ancestry, and similar data from Latin America, sub-Saharan Africa and South Asia are lacking. This under-representation is an unmet need in applying genetic factors to understand the pathogenesis, diagnosis and classification of SpA and PsA. This article provides a comprehensive overview of the epidemiology of spondyloarthritis — including axial spondyloarthritis, psoriatic arthritis and peripheral spondyloarthritis — worldwide, as well as the epidemiology of genetic factors implicated in these diseases.
{"title":"Global epidemiology of spondyloarthritis","authors":"John D. Reveille, Lihi Eder, Nelly Ziade, Percival D. Sampaio-Barros, Tae-Hwan Kim, Nurullah Akkoç, Matthew A. Brown","doi":"10.1038/s41584-025-01286-x","DOIUrl":"10.1038/s41584-025-01286-x","url":null,"abstract":"The worldwide epidemiology of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and peripheral spondyloarthritis, as well as of HLA-B27 and other MHC and non-MHC genes in these diseases, is reviewed herein. The frequency of axSpA is highest in circumpolar groups (such as Sami people and certain Indigenous American groups) and lowest in those of Japanese and African ancestry. The same pattern holds for PsA, although the overall prevalence of PsA seems much lower in East Asia, where it is less frequent than axSpA. The prevalence of PsA in people with psoriasis is increased where rheumatological assessment was carried out and seems to be increasing over time. HLA-B27 remains the most important genetic factor in axSpA susceptibility, although its frequency is lower in African American, South American and Middle Eastern populations than in others. The presence of HLA-B27 and other HLA alleles seems to be important in discerning clinical subsets of SpA and PsA, particularly those characterized by acute anterior uveitis or by axSpA with psoriasis, although these HLA-B27 and other MHC and non-MHC associations are derived from genome-wide association studies and other chip-based studies in large populations. These studies have been carried out mainly in populations of European and East Asian ancestry, and similar data from Latin America, sub-Saharan Africa and South Asia are lacking. This under-representation is an unmet need in applying genetic factors to understand the pathogenesis, diagnosis and classification of SpA and PsA. This article provides a comprehensive overview of the epidemiology of spondyloarthritis — including axial spondyloarthritis, psoriatic arthritis and peripheral spondyloarthritis — worldwide, as well as the epidemiology of genetic factors implicated in these diseases.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"580-598"},"PeriodicalIF":32.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145059336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：